Advertisement
Advertisement
U.S. Markets open in 5 hrs 1 min
Advertisement
Advertisement
Advertisement
Advertisement

InMed Pharmaceuticals Inc. (INM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.11-0.46 (-8.26%)
At close: 04:00PM EDT
5.00 -0.11 (-2.15%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.57
Open5.30
Bid0.00 x 1200
Ask0.00 x 2200
Day's Range5.00 - 5.49
52 Week Range5.00 - 59.25
Volume102,992
Avg. Volume690,784
Market Cap72.24M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-1.37
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.40
  • GlobeNewswire

    InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

    VANCOUVER, British Columbia, Sept. 23, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022. Conference Call & Webcast:Friday, September 23, 2022, at 10:00 AM Pacific Time, 01:00 PM Eastern TimeRegistration Link: https://register.vevent.com/register/BIa76ceda464264b3ca

  • GlobeNewswire

    InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022

    VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022. Conference Call & Webcast:Friday, September 23, 2022, at 10:00 AM Pacific Time, 01:00 PM Eastern TimeRegistration Link: https://register.vevent.com/register/BIa76ceda464264b3cae0b5ddb6e76a

  • GlobeNewswire

    InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

    VANCOUVER, British Columbia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, today announced the closing of its previously announced private placement with two healthcare-focused institutional investors for the issuance and sale of 691,245 of its common shares at a purchase price of $8.68 per share (or pre-funded warrant in lieu thereof) priced at-the-market under

Advertisement
Advertisement